M
mPharma
We make medicines affordable and accessible to patients
About mPharma
mPharma, founded in 2013 by Gregory Rockson, Daniel Shoukimas, and James Finucane, is a health technology company focused on improving access to affordable and quality medications for patients in Africa. The company was born out of the founders' direct experiences with the challenges of accessing prescription drugs in the region. Rockson, the CEO, has a background in public policy and global health, which informed the company's mission. He is joined by CPO Daniel Shoukimas and CTO James Finucane, who bring the technological expertise to build and scale the company's solutions.
Read full description
mPharma's business model revolves around partnering with pharmaceutical manufacturers, insurance companies, healthcare providers, and governments. The company operates a vendor-managed inventory system, which helps pharmacies manage their stock levels efficiently and reduces the risk of stockouts. This is complemented by a financing solution that helps pharmacies procure medicines without large upfront capital investments. For patients, mPharma offers a drug benefits service, making medications more affordable. The company's primary product is a comprehensive pharmacy management software that handles everything from inventory and ordering to patient records and point-of-sale operations. By creating a more efficient and connected supply chain, mPharma aims to become the primary healthcare provider for millions across the continent through its growing network of community pharmacies.
At a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Accra, Ghana
- Employees
- 399
- Open positions
- 3
- Dealroom signal
- 61.7/100
- Industry
- Health, Fintech
- Sub-industry
- Pharmaceutical, Mortgages & Lending
- Sector
- Biotech & Life Sciences, Risk Management, Analytics, Data Analytics, Biotechnology, Sustainable Development Goals, Biotech and Pharma, Hard Tech
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 2 companies, latest Sep 2022
- Capital deployed
- —
- Preferred round
- ACQUISITION
Latest news
Press, funding announcements and product moves mentioning mPharma.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Nov 2025 | $0 | — | Growth Investment Partners | ↗ |
| DEBTDebt | Jan 2022 | $5M | — | Citibank | ↗ |
Growth signals
Latest recorded traffic for mPharma is 3.8K monthly website visits, down 48.6% over the last three months. mPharma's team declined 5.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Alchemist Accelerator
Social Capital
Singularity Investments
Series A3 investors entered at this stage
Golden Palm Investments
4DX Ventures
Novastar Ventures
Series B and later11 investors entered at this stage
CDC Group
Jim Breyer
Dompé farmaceutici
Daniel Vasella
Citibank
JAM Fund
Unbound
Northstar
Lux Capital- TVTO Ventures
Growth Investment Partners
Other known investors1 additional known investor
Microsoft for Startups
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about mPharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See mPharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







